Analysts at Jefferies & Co. boosted the price target on pharmaceutical company Bristol Myers Squibb Co. (BMY) on Tuesday, stating that 2013 will be a pivotal year for shaping long-term growth.
The analysts maintain a “Buy” rating on BMY and see shares reaching $41. This new target suggests an 11% upside to Monday’s closing price of $36.93.
Bristol Myers shares were down slightly during morning trading on Tuesday. The stock is up about +15% over the past year.
The Bottom Line
Shares of Bristol Myers (BMY) have a dividend yield of 3.79% based on last night’s closing price of $36.93 and the company’s annualized dividend payout of $1.40 per share.
Bristol Myers Squibb Co. (BMY) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.